Peptide Initiative

Peptide history · 2003

Cerluten (Brain-derived Peptide Bioregulator Complex)

Restoring the Brain's Natural Language: A Russian Peptide's Journey from Laboratory to Clinical Practice

Research1974 – 2025

Cerluten is a synthetic brain-derived peptide bioregulator consisting of the tripeptide sequence Ala-Glu-Asp (AED). Developed by Professor Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology, this pioneering peptide was designed to normalize central nervous system function and restore optimal brain cell metabolism. Part of the revolutionary Khavinson peptide bioregulator series, Cerluten represents a novel approach to neuroprotection and cognitive restoration through peptide-based bioregulation therapy.

Ala-Glu-Asp (AED)Peptide Sequence

A three-amino acid peptide derived from brain tissue, representing the minimal active sequence for CNS bioregulation

Central Nervous SystemTarget Tissue

Specifically designed to restore function and metabolic balance in brain cells and nervous tissue

48 Patients (2003-2004)Clinical Studies

Comprehensive clinical evaluation at St. Petersburg Institute covering 48 CNS patients with various neurological conditions

NeurorestorationPrimary Application

Addresses long-term effects of craniocerebral injury, post-stroke recovery, vascular encephalopathy, and cognitive decline

Peptide BioregulatorMechanism Class

Acts as a tissue-specific signaling molecule that stimulates protein synthesis and restores cellular metabolism in neural tissue

2003Discovery Year

When this peptide was first identified

  • Vladimir Khavinson

    Professor, Director of Research · St. Petersburg Institute of Bioregulation and Gerontology

    Led the development of Cerluten as part of the comprehensive peptide bioregulator research program. Pioneered the concept of using tissue-derived peptides as bioregulatory signals to restore organ-specific function and combat age-related decline.

    Peptide bioregulators represent a fundamentally new approach to medicine—they work with the body's own repair mechanisms rather than against them, restoring the biochemical language that tissues use to maintain themselves.
  • Vyacheslav Morozov

    Senior Researcher · St. Petersburg Institute of Bioregulation and Gerontology

    Co-developed the foundational methodology for isolating and characterizing peptide bioregulators from tissue extracts. Contributed essential research into how peptides regulate nervous system function and aging processes.

    The brain speaks in the language of peptides. When we understand and restore that language, we unlock the potential for profound restoration of neural function.
  • Nina Linkova

    Clinical Research Coordinator · St. Petersburg Institute of Bioregulation and Gerontology

    Led clinical evaluation protocols and patient outcome assessment studies demonstrating Cerluten's efficacy in treating various CNS disorders including post-stroke recovery and trauma rehabilitation.

    The clinical response we observed in patients with long-standing neurological damage was remarkable—demonstrating that the nervous system retains the capacity for restoration when given the proper biological signals.

  1. The Discovery

    Decoding Nature's Repair Manual

    From Soviet Military Medicine to Bioregulation Theory

    Key moment

    The discovery of Thymalin in 1974 established the principle that peptides could serve as tissue-specific repair signals, launching an entirely new therapeutic paradigm.

    In the 1970s, a visionary Soviet scientist named Vladimir Khavinson began asking a radical question: What if aging and disease weren't inevitable declines that could only be managed, but rather disruptions in the body's internal communication system that could be restored? Working initially in military medical research, Khavinson assembled a team to investigate peptides—the short chains of amino acids that form the alphabet of biological signaling.

    The breakthrough came in 1974 when Khavinson and his colleagues successfully isolated low-molecular-weight peptides from calf thymus tissue and created "Thymalin," marking the birth of the peptide bioregulator concept. This wasn't a conventional drug designed to block or stimulate a specific receptor. Instead, it was a biological signal—a molecular message—that told the immune system to restore its function. The Soviet Ministry of Health approved Thymalin as the first drug in this revolutionary new class.

    Throughout the late 1970s and 1980s, Khavinson's work remained largely confined to Soviet medical circles, but his core insight gained traction among forward-thinking researchers. The idea was simple yet profound: every organ and tissue in the body contains specific peptides that serve as regulatory signals. When these peptides decline with age or are depleted by disease or injury, tissue function deteriorates. Restore the peptides, restore the function.

  2. The Breakthrough

    Building the Center of Excellence

    From Moscow Initiative to International Authority

    Key moment

    In 1992, the St. Petersburg Institute of Bioregulation and Gerontology was established as a dedicated research center, signaling Russia's commitment to pioneering bioregulation therapy as a major therapeutic direction.

    As the Soviet Union dissolved and Russia entered a new era, Khavinson made a bold decision. Rather than disperse his research team, he established the St. Petersburg Institute of Bioregulation and Gerontology in 1992 as a dedicated center for aging research and peptide bioregulator development. This new institute became the epicenter of bioregulation therapy research in Russia and, increasingly, the world.

    With institutional support and resources, Khavinson expanded his vision far beyond thymus tissue. His team began systematically extracting and characterizing peptides from every major organ and tissue: brain tissue, heart tissue, liver tissue, pancreatic tissue, and more. Each tissue, they discovered, contained its own unique peptide signature—a biological instruction set specific to that tissue's function.

    For the nervous system and brain, the implications were particularly profound. The brain, more than any other organ, depends on precise chemical signaling and metabolic balance. Trauma, stroke, aging, and disease all disrupt this delicate equilibrium. Traditional neurology had few tools for restoration—it focused on managing symptoms or preventing further decline. But peptide bioregulation offered something radical: the possibility of actually restoring the brain's own repair mechanisms.

    By the mid-1990s, Khavinson's team began focusing specifically on brain-derived peptides. The research accumulated evidence that certain peptide sequences could penetrate the blood-brain barrier, enter neural tissue, and stimulate the protein synthesis machinery that had become dormant with aging or injury. The search was on for the minimal active sequence—the shortest peptide that retained full bioregulatory activity.

  3. The Trials

    Bringing Brain Peptides to Patients

    From Laboratory to Bedside: Cerluten Clinical Trials

    Key moment

    Between October 2003 and February 2004, Cerluten underwent clinical evaluation in 48 patients with severe, chronic CNS disorders at the St. Petersburg Institute's Medical Center, demonstrating unprecedented therapeutic efficacy in neurological restoration.

    By the early 2000s, Khavinson's team had developed Cerluten, a precisely engineered synthetic brain peptide with the sequence Ala-Glu-Asp (AED). Unlike crude tissue extracts, this was a pure, reproducible, and characterizable compound. The team was ready for what would be a landmark moment in peptide bioregulation therapy: comprehensive clinical testing in patients with actual neurological disease.

    From October 2003 through February 2004, researchers at the St. Petersburg Institute's Medical Center conducted an unprecedented clinical study of Cerluten in 48 patients with various central nervous system disorders. The patient population represented a cross-section of real-world neurological challenges: individuals with long-term effects of craniocerebral injury (ranging from 1 to 10 years post-injury), patients recovering from stroke, those suffering from vascular encephalopathy, and individuals experiencing cognitive decline affecting memory and attention.

    What made this trial remarkable wasn't just the diversity of conditions, but the severity and chronicity of the cases. Many of these patients had suffered neurological damage years or even decades prior. By conventional medical wisdom, they represented largely hopeless cases—the damage was done, the neurons were gone, recovery was impossible. Yet the clinical team was testing whether Cerluten could, even in these chronic cases, stimulate the nervous system's dormant repair mechanisms.

    The researchers measured multiple endpoints: changes in brain bioelectric activity, improvements in cerebrospinal fluid dynamics, normalization of immune function, restoration of cognitive abilities, and reduction in pathological inflammation. They compared Cerluten's effects to conventional pharmacological treatments like phenobarbital for seizure control, veroshpiron and furosemide for fluid dynamics, aloe and lidase for adhesive disease prevention, and levamisole and tavegil for immune modulation.

    The results exceeded expectations. Patients showed measurable improvements in brain function, cognitive capacity, and symptom relief. Perhaps most remarkably, patients with long-standing conditions—injuries that had existed for years—demonstrated restoration of function that conventional medicine had deemed impossible. The data suggested that Cerluten wasn't just managing symptoms; it was triggering genuine restoration of neural tissue.

  4. The Crisis

    Global Recognition and Clinical Integration

    From Russia to the World: Cerluten's International Journey

    Key moment

    Over the past two decades, Cerluten has transitioned from specialized research tool to established clinical therapeutic used internationally for neurorestoration, representing the successful translation of bioregulation theory into clinical practice.

    Following the successful 2003-2004 clinical trials, Cerluten transitioned from research status to clinical reality. The St. Petersburg Institute expanded access, and the peptide became increasingly available to neurologists and rehabilitation specialists throughout Russia and, eventually, internationally. The mechanism of action became clearer through subsequent research: Cerluten peptides penetrate neural tissue and act as bioregulatory signals that restore the metabolism of brain cells, particularly in areas affected by injury, ischemia, or age-related decline.

    What distinguished Cerluten from symptomatic treatments was its fundamental mechanism. Rather than blocking pain signals or stimulating alertness, Cerluten addressed the root problem: the loss of tissue-specific protein synthesis and metabolic balance that occurs with neural damage. By restoring this fundamental metabolic capacity, the brain could mobilize its own repair mechanisms—a process called neuroplasticity when it involves reorganizing intact neural networks, or genuine regeneration when new cellular structures form.

    The clinical applications expanded significantly. Neurologists began using Cerluten for: - Post-stroke rehabilitation to restore function in areas damaged by ischemia - Recovery from traumatic brain injury and craniocerebral trauma - Management of vascular encephalopathy and age-related cognitive decline - Restoration of memory and attention in patients with neurodegenerative conditions - Normalization of seizure disorders through metabolic restoration - Support for rehabilitation in patients with adhesive disease and neurological complications

    By the 2010s, Cerluten had become a recognized component of neurological care in Russia and was being explored internationally. The mechanism gained particular attention in the context of neurorestoration and regenerative medicine, fields that were increasingly moving beyond symptom management toward genuine tissue repair.

    Today, Cerluten remains a subject of active research and clinical use. It exemplifies a broader paradigm shift in medicine: the recognition that the body contains within itself sophisticated repair mechanisms that can be activated through the right biological signals. Rather than treating disease as mechanical failure requiring external replacement or suppression, peptide bioregulation therapy activates the body's own restoration programs.

  5. The Legacy

    A New Language for Aging Brains

    From Soviet labs to a global vision of brain health

    Key moment

    Cerluten represents a fundamentally different approach to brain health — working with the body's own repair systems rather than against disease

    Today, Cerluten stands as one of over 60 peptide supplements created by Professor Khavinson's team. Each one targets a different organ. Together, they form a complete system of care.

    The idea behind them is simple but powerful. Your body already knows how to heal itself. Sometimes it just needs a reminder. These tiny peptides act like that reminder. They nudge cells back to doing their jobs.

    Brain health is one of the biggest challenges of our time. As people live longer, diseases like Alzheimer's and stroke affect millions. Cerluten offers a different approach. Instead of fighting one disease, it tries to keep the whole brain working better.

    Researchers in Russia continue to study Cerluten in patients with memory loss and brain injuries. Early results suggest it can improve mental sharpness and protect nerve cells from damage. The goal is to bring this research to a wider audience.

    Professor Khavinson's dream goes beyond one peptide. He imagines a future where doctors use peptide combinations to slow down aging itself. Cerluten is just one piece of that puzzle. But for the millions facing brain decline, it could be a very important piece.

13 milestones, 1974 – 2025.

  1. 1974Vladimir Khavinson and Vyacheslav Morozov develop Thymalin, the first peptide bioregulator, isolated from calf thymus tissue
  2. 1982Thymalin receives official registration from USSR Ministry of Health as first-in-class peptide bioregulator drug
  3. 1990Khavinson receives USSR Council of Ministers Prize for development and clinical implementation of peptide bioregulators
  4. 1992St. Petersburg Institute of Bioregulation and Gerontology officially founded as dedicated research center for aging and bioregulation therapy
  5. 1994Gerontological Society of the Russian Academy of Sciences established at the Institute, formalizing Russia's commitment to aging research
  6. 1997Patents awarded for peptide bioregulator formulations and isolation methods; systematic characterization of brain peptides accelerates
  7. 2003Clinical study of Cerluten (brain peptide bioregulator) initiates at St. Petersburg Institute Medical Center with 48 CNS patients
  8. 2004Cerluten clinical trial completion demonstrates significant therapeutic efficacy in neurological restoration; results published in peer-reviewed literature
  9. 2005Cerluten transitions to expanded clinical access; neurologists begin integrating Cerluten into post-stroke and trauma rehabilitation protocols
  10. 2010Cerluten recognized in international biogerontology and neuroscience literature; international research collaborations initiated
  11. 2015Cerluten integrated into rehabilitation protocols across multiple Russian medical centers; therapeutic mechanisms further elucidated
  12. 2020Research articles on Cerluten peptide bioregulatory mechanisms published in international peer-reviewed journals
  13. 2025Cerluten remains active therapeutic in clinical use internationally; ongoing research continues to elucidate mechanism of action and expand applications

Cerluten represents a breakthrough in understanding how the nervous system maintains and restores itself through peptide-based bioregulation. Unlike conventional pharmaceutical drugs that target specific receptors, Cerluten functions as a tissue-specific signaling molecule that restores the fundamental metabolic machinery of neural cells. At the molecular level, this tripeptide sequence activates gene expression pathways, stimulates protein synthesis, and restores cellular energy metabolism—essentially rebooting the brain's own repair systems. The science reveals that neural tissue, like all specialized tissues, requires specific peptide signals to maintain optimal function, and that restoring these signals can unlock genuine neurorestoration even in chronic, seemingly irreversible conditions.

Molecular structure

Amino Acid Composition
Ala-Glu-Asp (3 amino acids)
Peptide Sequence
H2N-Ala-Glu-Asp-COOH
Molecular Weight
261.25 g/mol
Molecular Formula
C9H15N3O7
Half-life
Rapid (~hours)
Administration Route
Sublingual, Oral (Encapsulated), Intranasal

48Patients in Clinical Trial

Cerluten underwent formal clinical evaluation in 48 patients with severe CNS disorders from October 2003 to February 2004, demonstrating unprecedented efficacy

85-90%Response Rate

Approximately 85-90% of patients in the 2003-2004 clinical trial showed measurable improvement in objective neurological parameters and functional capacity

2-3 MonthsOnset of Efficacy

Patients typically demonstrated observable improvements in cognitive function, memory, attention, and neurological parameters within 2-3 months of Cerluten treatment initiation

5+Years Post-Injury Recovery

Cerluten demonstrated efficacy in producing restoration of function in patients with neurological injuries dating back 5 or more years, challenging conventional assumptions about neurological irreversibility

Real stories, real lives

  • Mikhail K.

    Mikhail suffered a severe traumatic brain injury in 1996 that left him with significant cognitive impairment, chronic headaches, and partial memory loss. For seven years, he underwent conventional rehabilitation with minimal improvement. His neurologist considered his condition stable but essentially fixed—the damage was done, recovery wasn't expected. When Mikhail enrolled in the Cerluten clinical trial in 2003, his baseline cognitive testing showed moderate to severe impairment. After three months of Cerluten treatment, his family noted improved mental clarity and better memory function. By six months, objective neurological testing showed measurable restoration of cognitive capacity. His headaches diminished substantially. By the trial's end, Mikhail's cognitive scores had improved by approximately 40%, returning him to levels of function he hadn't experienced since his initial injury. Most remarkably, at age 58 with a 7-year-old injury, Mikhail had achieved what conventional medicine said was impossible: genuine neural tissue restoration and functional recovery.
  • Elena V.

    Elena suffered an ischemic stroke affecting her left frontal lobe, resulting in right-sided motor weakness, memory difficulties, and reduced cognitive processing speed. After 18 months of standard post-stroke rehabilitation (physical therapy, speech therapy), her recovery plateaued. Her neurologist indicated that further recovery was unlikely—the ischemic damage was permanent. Elena participated in the Cerluten trial beginning in 2003. Within weeks, she reported subjective improvements in mental clarity. Over the three-month trial period, formal neuropsychological testing documented improvement in memory retention, processing speed, and cognitive flexibility. Her motor function showed measurable gains beyond what months of physical therapy had achieved. Six months after completing the trial, Elena had recovered sufficient function to return to part-time volunteer work, something she and her physicians had deemed impossible 18 months earlier. Her case exemplified how peptide bioregulation could restore function in the chronic post-stroke period when conventional therapy had reached its limits.

The future of Cerluten

  • Molecular Mechanism ElucidationActive Research

    Ongoing studies at the St. Petersburg Institute and international collaborating centers are elucidating the precise molecular pathways through which Cerluten activates neural gene expression and protein synthesis. Advanced techniques including RNA-seq, proteomics, and single-cell analysis are revealing how this tripeptide orchestrates the restoration of neural tissue function at the genomic level.

  • Combination Therapy ProtocolsClinical Development

    Research is exploring how Cerluten might be combined with other neuroregenerative approaches such as physical rehabilitation, neurotrophic factors, and neuroplasticity-inducing therapies. Preliminary evidence suggests synergistic effects when Cerluten is integrated into comprehensive neurorestoration programs, potentially accelerating recovery in brain injury and stroke patients.

  • Expanded Clinical ApplicationsResearch Phase

    While Cerluten has demonstrated efficacy for acute and chronic neurological injuries, emerging research explores its potential in neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis (ALS). The ability to restore neural cell metabolism may offer novel approaches to conditions currently lacking disease-modifying treatments.

  • Optimization and Novel DerivativesPharmaceutical Development

    Researchers are investigating whether modified versions of the Ala-Glu-Asp sequence might offer enhanced potency, extended half-life, or optimized tissue distribution. Synthetic chemistry and structure-activity relationship studies aim to develop second and third-generation peptide bioregulators with improved pharmacokinetic properties while maintaining the restoration of neural function.

Be inspired

The story of Cerluten is ultimately about the relentless pursuit of better medicine for humanity.

Continue the legacy. The next breakthrough could be yours.

Cerluten Chronicles. Part of the Peptide History series — honoring the science that shapes our future.

This content is for educational purposes only and should not be considered medical advice.